Welcome to our dedicated page for Koninklijke Phil news (Ticker: PHG), a resource for investors and traders seeking the latest updates and insights on Koninklijke Phil stock.
Royal Philips (Koninklijke Philips N.V., NYSE: PHG) is a health technology company whose news flow centers on diagnostic imaging, ultrasound, image-guided therapy, monitoring, enterprise informatics and personal health. Company announcements frequently highlight AI-enabled systems, new product launches and strategic portfolio moves, giving investors and observers insight into how Philips develops and positions its health technology offerings.
Recent Philips news has featured AI-powered innovations in image-guided therapy and diagnostic imaging, such as LumiGuide 3D Device Guidance for light-based navigation during minimally invasive procedures, DeviceGuide for AI-assisted tracking of heart valve repair devices, and Verida, a detector-based spectral CT system with AI integrated across the imaging chain. The company also reports advances in MRI through its BlueSeal Horizon 3.0T platform and extended partnerships in neuroimaging, such as the integration of Cortechs.ai quantitative analytics into Philips MR workflows.
News items also cover enterprise informatics and cloud-based solutions, including the launch of Philips Management 15, a web-based diagnostic viewer that delivers full radiology capabilities through a browser and interfaces with AI tools and interactive reporting. In addition, Philips communicates on long-term partnerships with health systems, monitoring agreements and large-scale deployments of its Azurion image-guided therapy systems.
Corporate and portfolio developments appear regularly in the news stream. Examples include the agreement to acquire SpectraWAVE Inc. to expand intravascular imaging and physiology solutions, and the completed carve-out of the Philips Emergency Care business, which now operates as Heartstream under a Philips brand license. Earnings-related releases and Form 6-K summaries provide context on comparable order intake, sales trends, margins, productivity programs and outlook.
Investors and healthcare professionals following PHG news can use this page to track product introductions, AI and imaging milestones, strategic transactions and quarterly performance updates that shape Philips’ role in global health technology.
Royal Philips (NYSE: PHG) showcased its innovative portfolio of vendor-neutral radiology workflow solutions at the RSNA annual meeting from November 28 to December 2, 2021. The solutions focus on streamlining workflows for radiologists, technologists, and administrators through AI-driven informatics, enhancing diagnostic confidence and efficiency. Philips' new MR 5300 system, which received FDA 510(k) clearance, simplifies clinical tasks, while the company's commitment to sustainability is reinforced by its leadership in reducing CO2 emissions. Philips remains dedicated to improving healthcare outcomes and addressing workforce challenges in the radiology sector.
Philips has launched the world’s first spectral detector angio-CT solution at RSNA 2021, integrating breakthrough spectral CT imaging with real-time fluoroscopy. This innovative technology aims to enhance minimally invasive procedures in oncology, stroke, and trauma care. By combining the Spectral CT 7500 and Azurion with FlexArm, interventionalists gain immediate access to vital imaging modalities at the patient’s side, improving workflow and patient care. Philips is partnering with leading clinical institutions like Mayo Clinic to co-create this advanced imaging solution.
Royal Philips (NYSE: PHG) announced the launch of its new AI-powered MR 5300 and MR 7700 systems at the RSNA 2021 meeting. The MR 5300 system has received FDA 510(k) clearance and is designed for helium-free operations, enhancing sustainability and efficiency in outpatient clinics. The MR 7700 system features advanced multinuclear capabilities for improved imaging. Philips also introduced the AI-assisted MR Workspace, aimed at streamlining workflows and increasing productivity in radiology departments. The new portfolio emphasizes Philips' commitment to high-quality imaging and operational efficiency.
On November 22, 2021, Philips announced a collaboration with MedChat to integrate live chat and AI-driven chatbot services into its Patient Navigation Manager. This integration aims to enhance call center efficiency and expedite the resolution of patient inquiries in North America. The Patient Navigation Manager has shown significant success, with metrics indicating an 86% reduction in same-day cancellations and a 30% increase in referral conversions. The collaboration is part of Philips' commitment to improving patient management and outcomes through integrated health technology solutions.
Summary not available.
Philips (NYSE: PHG) has received FDA 510(k) clearance for its Liver Fat Quantification tools integrated into the EPIQ Elite and Affiniti ultrasound systems. This advancement aims to enhance early-stage fatty liver disease diagnosis, which affects about 25% of the global population. The tools will be showcased at the Radiological Society of North America annual meeting. Philips emphasizes that improved diagnostic capabilities will lead to better patient outcomes, allowing for timely lifestyle changes to mitigate liver disease progression.
Royal Philips (NYSE: PHG) announced on November 14, 2021, that its subsidiary, Philips Respironics, is addressing potential health risks linked to foam in certain sleep and respiratory devices. The company initiated a voluntary recall in June 2021. The FDA recently inspected a manufacturing facility, providing observations that will be addressed by Philips. Testing continues on new silicone replacement foam, with results showing acceptable outcomes. Philips is committed to the health of affected patients and will share findings with authorities following ongoing assessments.
Philips has received a USD 15.4 million grant from the Bill & Melinda Gates Foundation to enhance its obstetrics app development for the handheld ultrasound device, Lumify. This project aims to improve maternal healthcare, particularly in underserved communities, targeting around 2.5 billion people by 2030, with a focus on reducing pregnancy-related deaths. The initiative will empower midwives in low-income areas with AI technology, enabling early identification of complications in pregnancy, ultimately aiming to decrease both maternal and fetal mortality rates.
Royal Philips (NYSE: PHG) announces results from a real-world analysis of Medicare data showing significant benefits of intravascular ultrasound (IVUS) in peripheral vascular interventions. Key findings include a 32% reduction in major adverse limb events like amputations during lower extremity interventions among over 697,794 patients and a 31% reduction in repeat interventions, hospitalizations, or deaths during iliofemoral venous stenting. The study emphasizes IVUS's potential to optimize patient care and improve long-term health outcomes.
Amsterdam, the Netherlands – Royal Philips (NYSE: PHG) announced its acquisition of Cardiologs, a France-based medical technology innovator specializing in AI-driven cardiac diagnostics. This strategic acquisition, enhancing Philips' cardiac care offerings, is anticipated to close in the coming months. Although financial details remain undisclosed, the integration of Cardiologs' ECG analysis capabilities is expected to improve diagnostic accuracy and clinician workflow. Cardiologs' technology, supported by 20 million ECG recordings, aligns with Philips' aim for better patient outcomes and healthcare efficiency.